University Of California, San Francisco

Researchers from Arc Institute, Gladstone Institutes, and UCSF developed a novel epigenetic editing platform using CRISPRoff and CRISPRon technologies to modify up to five genes simultaneously in human T cells without DNA damage.

University of California, San Francisco researchers have developed a promising immunotherapy combination using LIGHT overexpression and anti-CTLA-4 antibodies that successfully eradicated colorectal cancer liver metastases in preclinical murine models.

Achieve Life Sciences has named Dr. Mark Rubinstein as Interim Chief Medical Officer, succeeding Dr. Cindy Jacobs as the company advances its smoking cessation drug cytisinicline.

Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.

The progressive supranuclear palsy (PSP) market is experiencing significant growth driven by emerging therapies including AZP2006 and AMX0035, which are advancing through clinical trials with promising results.

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.

Invivyd has established the SPEAR Study Group with leading researchers to investigate monoclonal antibody therapy for Long COVID and Post-Vaccination Syndrome, following anecdotal reports of symptom relief with PEMGARDA.

New ARTIOS Phase IIIb study data demonstrates that patients switching to Kesimpta after breakthrough disease on oral therapies achieved over 90% no evidence of disease activity (NEDA-3) with low annualized relapse rates.

A multinational study demonstrates that AI assistance significantly improves pathologists' accuracy in HER2 breast cancer scoring, with accuracy rates increasing from 89.1% to 96.1% when AI tools were utilized.

A retrospective analysis by Mass General Brigham and UCSF researchers found that glioblastoma patients taking gabapentin lived 4-6 months longer than those who didn't receive the medication.